No serious adverse events were observed during the study.īoth questions treated in this study, efficacy and safety, are important from a medical perspective because many persons take the agent studied in an effort to enhance their mental functioning and general well-being. This study did not reveal evidence of unknown drug-induced side effects or intolerance. Secondary outcomes supporting the notion of superiority of the active drug were found for both motor performance and emotional evaluation. No intergroup differences were found in self-estimated general health. Intergroup differences in self-estimated mental health as well as self-estimated quality of life were significant in favor of EGb 761. Secondary outcome measures are 15 tests and experimental procedures based on a neurobiologically based classification or taxonomy of functions. Primary outcome measures in this study are the subjects' judgment of their own mental health (MH), their general health (GH) and their quality of life (QoL) operationalized on the basis of three different visual analog scales (VAS). Safety and compliance were monitored after 1, 2, 3 and 4 weeks. Sixty six healthy volunteers aged between 50 and 65 years without age-associated cognitive impairment were randomized, 32 into the placebo and 34 into the EGb 761-treatment group (240 mg, t.i.d.).
GINKGO BILOBA BENEFICIOS PARA EL CEREBRO TRIAL
The trial was conducted as a 4-week, randomized, double-blind, placebo-controlled, parallel-group, monocentric study.
Thus, the objective of the present study was to evaluate the relatively short-term (i.e., 4 weeks) effects of EGb 761 on mental functioning and quality of life in healthy volunteers. There has been a lack of investigations examining the effects of Ginkgo biloba extract EGb 761 on mental functions and quality of life in healthy subjects with no cognitive impairment.
0 kommentar(er)
